查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1936385

美國子癇前症檢測市場：市場洞察、競爭格局與預測（2033 年）

U.S. Preeclampsia Laboratory Testing Market Insights, Competitive Landscape, and Market Forecast - 2033
出版日期: | 出版商: Fairfield Market Research | 英文 104 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

隨著醫療保健機構日益重視子癇前症（一種影響孕婦的嚴重高血壓疾病）的早期診斷和管理，美國子癇前症檢測市場正經歷顯著增長。及時檢測至關重要，因為如果未能及時發現，該疾病可能導致嚴重的母嬰併發症。鑑於公眾意識的提高、技術的進步以及高風險懷孕的增加，預計到 2026 年，美國子癇前症檢測市場規模將達到 11 億美元，到 2033 年將增長至 18 億美元，複合年增長率 (CAGR) 為 6.70%。

市場洞察

近年來，子癇前症檢測技術取得了顯著進步。現代診斷方法包括尿液和血液檢測，能夠檢測蛋白尿、腎臟和肝臟功能異常以及與子癇前症相關的特定生物標記。 這些檢測不僅有助於疾病的早期發現，也能幫助醫護人員監測病情嚴重程度。

免疫測定、高通量篩選和多重檢測等技術進步提高了子癇前症診斷的準確性和速度。結合即時檢測解決方案的引入，這些創新正在幫助臨床醫生及時幹預，降低母嬰風險。

此外，子癇前症發病率的上升，尤其是在患有高血壓、糖尿病和肥胖等潛在疾病的女性中，凸顯了可靠診斷解決方案的必要性。將檢測納入標準產前護理方案對於有效管理高風險懷孕至關重要。

市場驅動因素

美國子癇前症檢測市場的成長受到多種因素的推動。其中一個關鍵驅動因素是醫護人員和病患對孕產婦健康併發症的認識不斷提高。 目前的產前保健計畫強調早期篩檢和定期監測，從而提高了檢測的普及率。

技術創新也是關鍵驅動因素。先進的診斷平台，例如酶聯免疫吸附試驗 (ELISA)、生物標記檢測和快速即時檢測設備，提高了子癇前症檢測的靈敏度和特異性。這使得早期發現更加可行和可靠，從而能夠進行主動管理。

政府的各項措施和以婦幼健康為重點的公共衛生計畫也在推動市場成長。產前診斷檢測的資金投入、保險覆蓋範圍的擴大以及宣傳活動的開展，促使醫院和實驗室採用先進的子癇前症檢測方案。

由於孕婦年齡增長、肥胖以及生活方式相關疾病等原因，高風險妊娠的增加進一步推動了對子癇前症診斷檢測的需求。不斷增長的患者群體推動了對頻繁監測和先進檢測的需求，從而支持了市場的持續擴張。

商機

美國子癇前症檢測市場為成熟和新興的診斷公司提供了充足的機會。生物標記檢測、多重檢測和快速診斷的創新有望推動醫院、診所和診斷中心對這些檢測方法的採用。

診斷公司與醫療保健提供者之間的合作將推動市場滲透。對發現新的生物標記和建構更精準的檢測平台進行研發投資，可望帶來競爭優勢。此外，整合遠距醫療報告和遠端監測等數位化解決方案可以簡化檢測流程並改善患者護理。

區域分析

在北美妊娠高血壓檢測市場，美國憑藉其先進的醫療基礎設施、較高的公眾意識和尖端診斷技術的廣泛應用，佔領先地位。加州、德州、紐約州和佛羅裡達州是推動市場成長的主要地區，這些地區擁有大量三級醫院和婦幼保健中心。

雖然城市地區持續加快檢測普及，但得益於政府資助的產前保健項目和移動診斷服務的擴展，郊區和農村地區也在逐步迎頭趕上。預計這些措施將在預測期內改善市場覆蓋率和患者就醫便利性，並減少醫療保健服務的區域差異。

主要參與者

全球子癇前症檢測市場競爭激烈，主要參與者專注於產品創新、策略合作和研究計畫。代表性市場參與者包括：

  • DiabetOmics
  • DRG Instruments GmbH
  • F.羅氏有限公司
  • GestVision公司
  • Lifeassay Diagnostics（私人）有限公司
  • Metabolomic Diagnostics
  • Perkin Elmer公司
  • Progenity公司
  • Quidel公司
  • 西門子醫療
  • 賽默飛世爾科技公司

這些公司利用先進的診斷技術和生物標記研究，保持強大的市場地位，並滿足產前護理提供者和患者日益增長的需求。

市場區隔

為了全面了解全球子癇前症檢測市場的發展趨勢，可將其細分為以下幾個部分：

依檢測類型：

  • 尿液檢測
  • 血液檢測

依子癇前症類型：

  • 輕度子癇前症
  • 重度子癇前症

依最終用戶：

  • 醫院和診所
  • 診斷中心
  • 其他

依地區：

  • 美國

目錄

第一章：摘要整理摘要

第二章 市場概覽

  • 市場定義與細分
  • 市場動態
    • 驅動因素
    • 限制因素
    • 市場機遇
  • 價值鏈分析
  • 新冠疫情影響分析
  • 波特五力分析
  • 俄烏衝突的影響
  • PESTLE分析
  • 監理分析
  • 價格趨勢分析
    • 當前價格及未來預測（2025-2033年）
    • 價格影響因素

第三章 全球子癇前症檢測市場預測（2020-2033）

  • 全球子癇前症檢測市場依檢測類型劃分的全球子癇前程檢測市場預測（收入，單位：十億美元），2020-2033 年
    • 尿液檢測
    • 血液檢測
  • 依子癇前症類型劃分的全球子癇前症檢測市場預測（收入，單位：十億美元），2020-2033 年
    • 輕度子癇前症
    • 重度子癇前症
  • 依最終用戶劃分的全球子癇前症檢測市場預測（價值，單位：十億美元），2020-2033 年
    • 醫院和診所
    • 診斷中心
    • 其他
  • 依地區劃分的全球子癇前期檢測市場預測（價值，單位：十億美元），2020-2033 年
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東東非和非洲

第四章：北美子癇前症檢測市場展望（2020-2033）

第五章：歐洲子癇前症檢測市場展望（2020-2033）

第六章：亞太地區子癇前症檢測市場展望（2020-2033）

第七章：拉丁美洲子癇前症檢測市場展望（2020-2033）

第八章：中東與非洲子癇前症檢測市場展望（2020-2033）

第九章：競爭格局

  • 公司與細分市場熱力圖
  • 公司市佔率分析2025
  • 競爭格局概覽
  • 公司簡介
    • DiabetOmics
    • DRG Instruments GmbH
    • F. Hoffmann-La Roche Ltd.
    • GestVision, Inc.
    • Lifeassay Diagnostics (Pty) Ltd.
    • Metabolomic Diagnostics
    • Perkin Elmer, Inc.
    • Progenity, Inc.
    • Quidel Corporation
    • Siemens Healthineers

第十章附錄

簡介目錄

The U.S. Preeclampsia Laboratory Testing Market is experiencing notable growth as healthcare providers increasingly focus on early diagnosis and management of preeclampsia-a serious hypertensive disorder affecting pregnant women. The condition, if left undetected, can result in severe complications for both mother and child, making timely laboratory testing essential. In response to rising awareness, technological advancements, and the growing prevalence of high-risk pregnancies, the U.S. market for preeclampsia laboratory testing is projected to reach USD 1.1 billion by 2026 and is expected to expand to USD 1.8 billion by 2033, representing a compound annual growth rate (CAGR) of 6.70%.

Market Insights

Laboratory testing for preeclampsia has progressed significantly over the years. Modern diagnostics include both urine and blood-based tests, allowing for the detection of proteinuria, kidney and liver function abnormalities, and specific biomarkers associated with preeclampsia. These tests not only help identify the condition early but also assist healthcare professionals in monitoring its severity.

Technological advancements such as immunoassays, high-throughput screening, and multiplex testing panels have enhanced the accuracy and speed of preeclampsia diagnosis. Combined with the adoption of point-of-care testing solutions, these innovations are helping clinicians provide timely interventions, reducing maternal and neonatal risks.

Furthermore, increasing incidences of preeclampsia, particularly among women with pre-existing conditions like hypertension, diabetes, or obesity, underscore the growing need for reliable diagnostic solutions. The integration of laboratory testing into standard prenatal care protocols has become critical in managing high-risk pregnancies effectively.

Market Drivers

Several factors are fueling the growth of the U.S. preeclampsia laboratory testing market. One of the primary drivers is growing awareness of maternal health complications among healthcare professionals and patients alike. Prenatal care programs now emphasize early screening and regular monitoring, prompting higher adoption of laboratory tests.

Technological innovation is another key driver. Advanced diagnostic platforms, including enzyme-linked immunosorbent assays (ELISA), biomarker panels, and rapid point-of-care devices, have improved both sensitivity and specificity in detecting preeclampsia. This has made early detection more feasible and reliable, enabling proactive management.

Government initiatives and public health programs focusing on maternal and child health are also supporting market growth. Funding for prenatal diagnostic testing, insurance coverage, and awareness campaigns have collectively encouraged hospitals and diagnostic laboratories to incorporate advanced preeclampsia testing solutions.

The rising number of high-risk pregnancies, influenced by delayed childbirth, obesity, and lifestyle-related health conditions, has further amplified demand for preeclampsia diagnostic tests. As the patient pool grows, the need for frequent monitoring and advanced testing continues to rise, supporting sustained market expansion.

Business Opportunities

The U.S. preeclampsia laboratory testing market presents ample opportunities for both established and emerging diagnostic companies. Innovations in biomarker detection, multiplex assays, and rapid diagnostics are expected to drive adoption across hospitals, clinics, and diagnostic centers.

Collaborations between diagnostic companies and healthcare providers can enhance market penetration. Investment in research and development to discover novel biomarkers and create more precise testing platforms will likely provide a competitive edge. Moreover, integrating digital solutions, such as telemedicine-enabled reporting and remote monitoring, can streamline testing processes and improve patient care.

Regional Analysis

The United States dominates the North American preeclampsia laboratory testing market due to its advanced healthcare infrastructure, high awareness levels, and availability of cutting-edge diagnostic technologies. Key regions contributing to market growth include California, Texas, New York, and Florida, which host a concentration of tertiary care hospitals and maternal health centers.

Urban centers continue to adopt laboratory testing at a faster pace, while suburban and rural areas are gradually catching up thanks to government-funded prenatal programs and mobile diagnostic initiatives. These efforts are expected to improve market reach and patient access over the forecast period, reducing regional disparities in healthcare services.

Key Players

The U.S. preeclampsia laboratory testing market is highly competitive, with leading companies focusing on product innovation, strategic partnerships, and research initiatives. Prominent market participants include:

  • DiabetOmics
  • DRG Instruments GmbH
  • F. Hoffmann-La Roche Ltd.
  • GestVision, Inc.
  • Lifeassay Diagnostics (Pty) Ltd.
  • Metabolomic Diagnostics
  • Perkin Elmer, Inc.
  • Progenity, Inc.
  • Quidel Corporation
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

These companies are leveraging advanced diagnostic technologies and biomarker research to maintain a strong presence in the market while addressing the growing needs of prenatal healthcare providers and patients.

Market Segmentation

The U.S. preeclampsia laboratory testing market can be segmented to provide a comprehensive understanding of its dynamics:

By Test Type:

  • Urine Tests
  • Blood Tests

By Preeclampsia Type:

  • Mild Preeclampsia
  • Severe Preeclampsia

By End User:

  • Hospitals and Clinics
  • Diagnostic Centres
  • Others

By Region:

  • U.S.

Table of Contents

1. Executive Summary

  • 1.1. U.S. Preeclampsia Laboratory Testing Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Fiver Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 3.1. Global U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Urine Tests
    • 3.1.2. Blood Tests
  • 3.2. Global U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 3.2.1. Mild Preeclampsia
    • 3.2.2. Severe Preeclampsia
  • 3.3. Global U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.3.1. Hospitals and Clinics
    • 3.3.2. Diagnostic Centres
    • 3.3.3. Others
  • 3.4. Global U.S. Preeclampsia Laboratory Testing Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 4.1. North America U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Urine Tests
    • 4.1.2. Blood Tests
  • 4.2. North America U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 4.2.1. Mild Preeclampsia
    • 4.2.2. Severe Preeclampsia
  • 4.3. North America U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.3.1. Hospitals and Clinics
    • 4.3.2. Diagnostic Centres
    • 4.3.3. Others
  • 4.4. North America U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 4.4.2. U.S. U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 4.4.3. U.S. U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 4.4.4. Canada U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 4.4.5. Canada U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 4.4.6. Canada U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 5.1. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Urine Tests
    • 5.1.2. Blood Tests
  • 5.2. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 5.2.1. Mild Preeclampsia
    • 5.2.2. Severe Preeclampsia
  • 5.3. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.3.1. Hospitals and Clinics
    • 5.3.2. Diagnostic Centres
    • 5.3.3. Others
  • 5.4. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.2. Germany U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.3. Germany U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.4. Italy U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.5. Italy U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.6. Italy U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.7. France U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.8. France U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.9. France U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.10. U.K. U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.11. U.K. U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.12. U.K. U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.13. Spain U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.14. Spain U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.15. Spain U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.16. Russia U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.17. Russia U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.18. Russia U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.19. Rest of Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.20. Rest of Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.21. Rest of Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Urine Tests
    • 6.1.2. Blood Tests
  • 6.2. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 6.2.1. Mild Preeclampsia
    • 6.2.2. Severe Preeclampsia
  • 6.3. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.3.1. Hospitals and Clinics
    • 6.3.2. Diagnostic Centres
    • 6.3.3. Others
  • 6.4. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.2. China U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.3. China U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.4. Japan U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.5. Japan U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.6. Japan U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.7. South Korea U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.8. South Korea U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.9. South Korea U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.10. India U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.11. India U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.12. India U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.13. Southeast Asia U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.14. Southeast Asia U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.15. Southeast Asia U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.16. Rest of SAO U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.17. Rest of SAO U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.18. Rest of SAO U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 7.1. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Urine Tests
    • 7.1.2. Blood Tests
  • 7.2. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 7.2.1. Mild Preeclampsia
    • 7.2.2. Severe Preeclampsia
  • 7.3. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.3.1. Hospitals and Clinics
    • 7.3.2. Diagnostic Centres
    • 7.3.3. Others
  • 7.4. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.2. Brazil U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 7.4.3. Brazil U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 7.4.4. Mexico U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.5. Mexico U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 7.4.6. Mexico U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 7.4.7. Argentina U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.8. Argentina U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 7.4.9. Argentina U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 7.4.10. Rest of LATAM U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.11. Rest of LATAM U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 7.4.12. Rest of LATAM U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Urine Tests
    • 8.1.2. Blood Tests
  • 8.2. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 8.2.1. Mild Preeclampsia
    • 8.2.2. Severe Preeclampsia
  • 8.3. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.3.1. Hospitals and Clinics
    • 8.3.2. Diagnostic Centres
    • 8.3.3. Others
  • 8.4. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.2. GCC U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.3. GCC U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 8.4.4. South Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.5. South Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.6. South Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 8.4.7. Egypt U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.8. Egypt U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.9. Egypt U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 8.4.10. Nigeria U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.11. Nigeria U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.12. Nigeria U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 8.4.13. Rest of Middle East U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.14. Rest of Middle East U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.15. Rest of Middle East U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. DiabetOmics
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. DRG Instruments GmbH
    • 9.4.3. F. Hoffmann-La Roche Ltd.
    • 9.4.4. GestVision, Inc.
    • 9.4.5. Lifeassay Diagnostics (Pty) Ltd.
    • 9.4.6. Metabolomic Diagnostics
    • 9.4.7. Perkin Elmer, Inc.
    • 9.4.8. Progenity, Inc.
    • 9.4.9. Quidel Corporation
    • 9.4.10. Siemens Healthineers

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations